Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +2.30% 22.25p 22.00p 22.50p 22.25p 22.00p 22.00p 341,549.00 16:27:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.8 -9.5 - 24.25

Motif Bio (MTFB) Latest News

More Motif Bio News
Motif Bio Takeover Rumours

Motif Bio (MTFB) Share Charts

1 Year Motif Bio Chart

1 Year Motif Bio Chart

1 Month Motif Bio Chart

1 Month Motif Bio Chart

Intraday Motif Bio Chart

Intraday Motif Bio Chart

Motif Bio (MTFB) Discussions and Chat

Motif Bio (MTFB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:07:4322.2513,0002,892.50O
16:27:4622.2520,0004,450.00AT
16:27:4122.2220,0004,443.76O
16:24:3422.2022,4664,987.45O
15:29:1122.1210,2562,268.18O
View all Motif Bio trades in real-time

Motif Bio (MTFB) Top Chat Posts

DateSubject
02/12/2016
08:20
Motif Bio Daily Update: Motif Bio is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTFB. The last closing price for Motif Bio was 21.75p.
Motif Bio has a 4 week average price of 29.21p and a 12 week average price of 42.31p.
The 1 year high share price is 67p while the 1 year low share price is currently 21.50p.
There are currently 109,010,496 shares in issue and the average daily traded volume is 780,994 shares. The market capitalisation of Motif Bio is £24,254,835.36.
23/11/2016
11:47
runwaypaul: sonnews Two shares in the IPO cost 56p (28p x 2) If sold at 24p each (48p) gives a loss of 8p. Exercise price per Warrant is 32.2p, which means the share price has to be 40.2p just to break even (8p plus 32.2p). As IIs aren't charitable foundations, it appears unlikely that Warrants will be exercised before the price is above 60p...time will tell.
19/11/2016
21:48
colebrooke: Twitter hashtag $MTFBWhatever you think of Twitter it reaches a wide audience.I've noticed increased coverage in the last day or so particularly from the US on the hashtag $MTFB.My point is the stock is gaining coverage amongst the Twitter stock/share trading audience. This should impact positively on interest in the stock and therefore drive Nasdaq trading and the share price.
12/8/2016
14:58
123prezzie: lanb5004. In your post 706 you say that the 'main holder' is supporting the NASDAQ fund raising. You don't say who you consider to be the main holder. If it is Amphion (AMP), who held 26% at 31/12/15, then I suggest you need to define what you mean by 'support'. AMP appears to be pretty short of cash and has already pledged well over half its MTFB shares as collateral against loans charging 10% (!) interest. The latest tranche is covered by the MTFB RNS above dated 18/7/16 where AMP has borrowed $750,000 with 1.4m MTFB shares as security ie an implied value of about 42p/share. Followers of Quindell and similar will know that the way these deals usually work is that the lender, probably with the benefit of a Put arrangement, sells if the share price falls near 42p, thus recouping the loan. MTFB is unlikely to survive for many months unless it can convince investors that its products will be successful. I strongly recommend that any investor, actual or potential, should read the AMP and MTFB accounts and then tell me if/where I am wrong.
09/8/2016
10:13
scott1000: Takeover bid?? that would stall the listing or the 55% variance between the IPO price of 47p and mtfb price of 63p yesterday... whatever it is.. I'm sure it will be made clear in time
15/7/2016
06:36
apad: IC: MOTIF BIO (MTFB) What we said: Buy When: 28 April 2016 Price: 42p Share price change to date: +14% Antibiotics specialist Motif Bio (MTFB) is looking stateside for its next injection of capital to help fund the final trial of its ground-breaking antibiotic iclaprim. The Aim-traded company has filed an application to list on the tech-heavy US Nasdaq index and plans to raise up to $60m (£45m) in the process. It’s not just for the money that this listing is attractive. Joining Nasdaq brings Motif closer to the Food and Drug Administration (FDA) – the regulatory body in the US which is responsible for approving all new drugs before launch into the world’s biggest healthcare market. Furthermore, US investors are generally thought to be less risk averse and therefore may be more willing to provide funds for the clinical trial as well as bidding up the share price. With the potential to launch the first new class of antibiotic for 30 years, Motif Bio is certainly an exciting company. Now, with easier access to cash thanks to a US listing, the investment case looks all the more attractive. Buy at 48p. MB Buy
27/5/2016
09:29
timberwolf3: http://www.investorschronicle.co.uk/2016/05/26/shares/news-and-analysis/lord-o-neill-calls-for-antibiotics-levy-rxtgxqxFCpXEJYmXeFtUjO/article.html This suggestion was met with glee by investors in small-cap antibiotics company Motif Bio (MTFB) - a recent IC buy tip - which has a novel antibiotic in the late stage of clinical trials. The group's share price rocketed 10 per cent last Thursday - the day the report was published - amid speculation that Motif could be a target for extra funding should the report's calls be enforced.
23/5/2016
08:23
timberwolf3: www.menafn.com/1094778683/These-pocket-rocket-superbug-stocks-could-fly Motif Bio Plc (LON:MTFB) You will have read a lot on Motif if you'd been following our coverage since the company listed here in London just over a year ago. In that time its progress has been remarkable, though not fully reflected in the share price, which has more than doubled since IPO. Its drug, Iclaprim, which is now in phase III clinical trials, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP). This includes hard-to-treat conditions caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings. Since listing in April 2015, Motif has met an aggressive timetable to get to the point of dosing patients with iclaprim. It has obtained regulatory approvals to commence phase III trials; raised 25m to fund the trials and appointed Covance to conduct the trials. It has also gained qualified infectious disease product designation, giving iclaprim up to 10 years of US market exclusivity and fast-track designation for iclaprim. With a valuation of 48mln, it is fair to say the UK market is overlooking the potential of Motif. Drugs giant Actavis paid427mln for the company developing Dalvance, an antibiotic similar to Iclaprim that is now on the market. ORBACTIV is another similar drug out there and the jewel in the crown for The Medicines Company, listed on NASDAQ in the US and worth 1.7bn.
03/5/2016
14:04
3rd eye: FULL BROKER NOTE FROM Shard.......... 3rd May 2016 Pharmaceuticals & Biotech Source: London Stock Exchange Market data EPIC/TKR MTFB Price (p) 47.5 12m High (p) 70.5 12m Low (p) 21.0 Shares (m) 108.6 Mkt Cap (£m) 51.7 EV (£m) 34.6 Free Float* 39% Market AIM www.shardcapitalstockbrokers.com/downloads/MTFBShardMay2016.pdf
09/3/2016
12:39
regandharry5: Current share price showing 45p...Offer price 44.5p. ???????
18/8/2015
09:53
regandharry5: Antibiotics in the news again, every time the over use of current antibiotics and how ineffiecent they are is raised the MTFB share price rises.
Motif Bio share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20161202 19:56:05